340 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Allergan Responds to Investor's Call for CEO/Chair Role Split http://www.zacks.com/stock/news/355578/allergan-responds-to-investors-call-for-ceo-chair-role-split?cid=CS-ZC-FT-355578 Feb 20, 2019 - Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.
Okta (OKTA) to Report Q4 Earnings: How Are Things Shaping Up? http://www.zacks.com/stock/news/357603/okta-okta-to-report-q4-earnings-how-are-things-shaping-up?cid=CS-ZC-FT-357603 Mar 04, 2019 - Okta's (OKTA) fourth-quarter fiscal 2019 top-line is likely to benefit from its solid customer base despite higher expenses.
J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression http://www.zacks.com/stock/news/357836/jjs-jnj-nasal-spray-spravato-gets-fda-nod-for-depression?cid=CS-ZC-FT-357836 Mar 06, 2019 - J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression
Spero Gets Fast Track Designation for SPR994, Shares Improve http://www.zacks.com/stock/news/368643/spero-gets-fast-track-designation-for-spr994-shares-improve?cid=CS-ZC-FT-368643 Apr 01, 2019 - Spero???s (SPRO) SPR994 receives Fast Track designation by the FDA for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis.
Will Allergan (AGN) Beat Estimates Again in Its Next Earnings Report? http://www.zacks.com/stock/news/369354/will-allergan-agn-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-369354 Apr 02, 2019 - Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU http://www.zacks.com/stock/news/371503/pharma-stock-roundup-nvs-inks-immunology-deal-pfe-teva-get-drug-approvals-in-eu?cid=CS-ZC-FT-371503 Apr 05, 2019 - Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Alkermes Reports Positive Data From Schizophrenia Study http://www.zacks.com/stock/news/377786/alkermes-reports-positive-data-from-schizophrenia-study?cid=CS-ZC-FT-377786 Apr 10, 2019 - Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.
Is a Beat in Store for Editas (EDIT) This Earnings Season? http://www.zacks.com/stock/news/402783/is-a-beat-in-store-for-editas-edit-this-earnings-season?cid=CS-ZC-FT-402783 Apr 25, 2019 - On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.
Can Allergan (AGN) Beat Earnings Estimates Again in Q1? http://www.zacks.com/stock/news/406700/can-allergan-agn-beat-earnings-estimates-again-in-q1?cid=CS-ZC-FT-406700 May 01, 2019 - Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales
Company News For Jun 20, 2019 http://www.zacks.com/stock/news/432199/company-news-for-jun-20-2019?cid=CS-ZC--432199 Jun 20, 2019 - Companies In The News Are: VIAB,CBS,ADBE,X,AGN,IRWD

Pages: 1...293031323334

<<<Page 34